Accueil   Diary - News   All news First sales of Flu Vaccines Produced on Valneva’s EB66® Cell-Line

First sales of Flu Vaccines Produced on Valneva’s EB66® Cell-Line

valvena photos pied de pageValneva to begin receiving royalties for an EB66®-based human vaccine in
2016


Valneva SE (“Valneva” or “the Company”), a leading pure play vaccine company, announces today that GlaxoSmithKline (GSK) in collaboration with one of its partners has for the first time supplied pre-pandemic influenza vaccines based on Valneva’s EB66® cell line.

 

Read the press release